Cite
HARVARD Citation
Nathan, P. et al. (2022). A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease. Alzheimer's & dementia. 8 (1), p. n/a. [Online].